NICE may reject Inhaled Insulin
April 19, 2006 on 11:59 am | In Prescribing Extra - Drugs |
Print
|
The National Institute of Health and Clinical Excellence (NICE) has issued an Appraisal Consultation Document for Inhaled Insulin (Exubera)® for Type I and Type II Diabetes.
This Appraisal is a preliminary recommendation and subject to change before publication however this document states that NICE do not recommend Inhaled Insulin for use on the NHS unless it is part of a clinical trial.
The BBC and Guardian have already reported this information.
Inhaled Insulin has many limitations in general use as discussed already. In addition to these clinical concerns this new product is likely to cost more at £1,100 per patient per year compared to £300 for injected insulin.
Action: Clinicians involved in the treatment of diabetes may be asked about this product by patients and should be aware of current information.
Bookmark in del.icio.us